



## Clinical trial results:

### A randomised, double blind, placebo-controlled phase I study investigating the safety of ALK HDM tablet in children

#### Summary

EudraCT number	2007-000402-67
Trial protocol	ES
Global end of trial date	01 April 2008

#### Results information

Result version number	v1 (current)
This version publication date	16 February 2016
First version publication date	26 July 2015

#### Trial information

##### Trial identification

Sponsor protocol code	MT-03
-----------------------	-------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	ALK-Abelló S.A.
Sponsor organisation address	Miguel Fleta, 19, Madrid, Spain, E-28037
Public contact	Clinical Development, ALK, +45 45 74 75 76, ClinicalTrials@alk.net
Scientific contact	Clinical Development, ALK, +45 45 74 75 76, ClinicalTrials@alk.net

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 April 2008
Is this the analysis of the primary completion data?	Yes
Primary completion date	01 April 2008
Global end of trial reached?	Yes
Global end of trial date	01 April 2008
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To identify a dose range of the ALK house dust mite tablet (SQ HDM SLIT-tablet) that has a safety profile that will allow once-daily intake (as self-medication) by 5-14 year old children with allergic asthma (with or without rhinitis) due to house dust mites.

Protection of trial subjects:

Dose groups were treated in a staggered manner at intervals of approximately 2 weeks. A safety committee reviewed the initial safety data of the previous dose (-s), and only by their approval did the trial enter the next (higher) level of dose strength.

Background therapy:

Subjects being treated for asthma continued the prescribed asthma medication during the trial.

Evidence for comparator:

Placebo comparator

Actual start date of recruitment	13 September 2007
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 72
Worldwide total number of subjects	72
EEA total number of subjects	72

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	59
Adolescents (12-17 years)	13
Adults (18-64 years)	0
From 65 to 84 years	0

85 years and over	0
-------------------	---

## Subject disposition

### Recruitment

Recruitment details:

Subjects were recruited from 4 clinical groups in Spain

### Pre-assignment

Screening details:

A total of 78 subjects were screened for this trial. Six subjects failed screening.

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Blinding implementation details:

The IMPs were produced so that all tablets were identical in appearance, smell and taste. In order to maintain the blinding, subjects within each dose group received the same number of tablets, whether they received tablet containing active ingredient or not.

Dose groups 0.5, 1, 3 and 6 SQ-HDM received one tablet daily and dose groups 9 and 12 SQ-HDM received two tablets daily to obtain a daily-dose.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	0.5 SQ-HDM

Arm description:

active treatment

Arm type	Experimental
Investigational medicinal product name	SQ HDM SLIT-tablet
Investigational medicinal product code	
Other name	ALK HDM tablet
Pharmaceutical forms	Sublingual tablet
Routes of administration	Sublingual use

Dosage and administration details:

The tablet (-s) were to be taken out of the blister pack with dry fingers and placed under the tongue (at the same time in the case of two tablets). After 1 minute the saliva was to be swallowed. Subjects were not to eat or drink for 5 minutes after administration of IMP.

Administration was to take place at a time of the day when children were under observation. At days 1, 2, 8, 15 and 22, medication was performed at the trial site. At days 3-7, 9-14, 16-21 and 23-28, intake of the tablet was performed at home (self-medicating).

<b>Arm title</b>	1 SQ-HDM
------------------	----------

Arm description:

active treatment

Arm type	Experimental
Investigational medicinal product name	SQ HDM SLIT-tablet
Investigational medicinal product code	
Other name	ALK HDM tablet
Pharmaceutical forms	Sublingual tablet
Routes of administration	Sublingual use

Dosage and administration details:

The tablet (-s) were to be taken out of the blister pack with dry fingers and placed under the tongue (at the same time in the case of two tablets). After 1 minute the saliva was to be swallowed. Subjects were not to eat or drink for 5 minutes after administration of IMP.

Administration was to take place at a time of the day when children were under observation. At days 1, 2, 8, 15 and 22, medication was performed at the trial site. At days 3-7, 9-14, 16-21 and 23-28, intake of the tablet was performed at home (self-medicating).

<b>Arm title</b>	3 SQ-HDM
Arm description: active treatment	
Arm type	Experimental
Investigational medicinal product name	SQ HDM SLIT-tablet
Investigational medicinal product code	
Other name	ALK HDM tablet
Pharmaceutical forms	Sublingual tablet
Routes of administration	Sublingual use

Dosage and administration details:

The tablet (-s) were to be taken out of the blister pack with dry fingers and placed under the tongue (at the same time in the case of two tablets). After 1 minute the saliva was to be swallowed. Subjects were not to eat or drink for 5 minutes after administration of IMP.

Administration was to take place at a time of the day when children were under observation. At days 1, 2, 8, 15 and 22, medication was performed at the trial site. At days 3-7, 9-14, 16-21 and 23-28, intake of the tablet was performed at home (self-medicating).

<b>Arm title</b>	6 SQ-HDM
Arm description: active treatment	
Arm type	Experimental
Investigational medicinal product name	SQ HDM SLIT-tablet
Investigational medicinal product code	
Other name	ALK HDM tablet
Pharmaceutical forms	Sublingual tablet
Routes of administration	Sublingual use

Dosage and administration details:

The tablet (-s) were to be taken out of the blister pack with dry fingers and placed under the tongue (at the same time in the case of two tablets). After 1 minute the saliva was to be swallowed. Subjects were not to eat or drink for 5 minutes after administration of IMP.

Administration was to take place at a time of the day when children were under observation. At days 1, 2, 8, 15 and 22, medication was performed at the trial site. At days 3-7, 9-14, 16-21 and 23-28, intake of the tablet was performed at home (self-medicating).

<b>Arm title</b>	9 SQ-HDM
Arm description: active treatment	
Arm type	Experimental
Investigational medicinal product name	SQ HDM SLIT-tablet
Investigational medicinal product code	
Other name	ALK HDM tablet
Pharmaceutical forms	Sublingual tablet
Routes of administration	Sublingual use

Dosage and administration details:

The tablet (-s) were to be taken out of the blister pack with dry fingers and placed under the tongue (at the same time in the case of two tablets). After 1 minute the saliva was to be swallowed. Subjects were not to eat or drink for 5 minutes after administration of IMP.

Administration was to take place at a time of the day when children were under observation. At days 1, 2, 8, 15 and 22, medication was performed at the trial site. At days 3-7, 9-14, 16-21 and 23-28, intake

of the tablet was performed at home (self-medicating).

<b>Arm title</b>	12 SQ-HDM
Arm description: active treatment	
Arm type	Experimental
Investigational medicinal product name	SQ HDM SLIT-tablet
Investigational medicinal product code	
Other name	ALK HDM tablet
Pharmaceutical forms	Sublingual tablet
Routes of administration	Sublingual use

Dosage and administration details:

The tablet (-s) were to be taken out of the blister pack with dry fingers and placed under the tongue (at the same time in the case of two tablets). After 1 minute the saliva was to be swallowed. Subjects were not to eat or drink for 5 minutes after administration of IMP.

Administration was to take place at a time of the day when children were under observation. At days 1, 2, 8, 15 and 22, medication was performed at the trial site. At days 3-7, 9-14, 16-21 and 23-28, intake of the tablet was performed at home (self-medicating).

<b>Arm title</b>	Placebo
Arm description: -	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Sublingual tablet
Routes of administration	Sublingual use

Dosage and administration details:

The tablet (-s) were to be taken out of the blister pack with dry fingers and placed under the tongue (at the same time in the case of two tablets). After 1 minute the saliva was to be swallowed. Subjects were not to eat or drink for 5 minutes after administration of IMP.

Administration was to take place at a time of the day when children were under observation. At days 1, 2, 8, 15 and 22, medication was performed at the trial site. At days 3-7, 9-14, 16-21 and 23-28, intake of the tablet was performed at home (self-medicating).

<b>Number of subjects in period 1</b>	0.5 SQ-HDM	1 SQ-HDM	3 SQ-HDM
Started	9	9	9
Completed	9	9	9

<b>Number of subjects in period 1</b>	6 SQ-HDM	9 SQ-HDM	12 SQ-HDM
Started	9	9	9
Completed	9	9	9

<b>Number of subjects in period 1</b>	Placebo
Started	18
Completed	18

## Baseline characteristics

### Reporting groups

Reporting group title	0.5 SQ-HDM
Reporting group description:	
active treatment	
Reporting group title	1 SQ-HDM
Reporting group description:	
active treatment	
Reporting group title	3 SQ-HDM
Reporting group description:	
active treatment	
Reporting group title	6 SQ-HDM
Reporting group description:	
active treatment	
Reporting group title	9 SQ-HDM
Reporting group description:	
active treatment	
Reporting group title	12 SQ-HDM
Reporting group description:	
active treatment	
Reporting group title	Placebo
Reporting group description: -	

Reporting group values	0.5 SQ-HDM	1 SQ-HDM	3 SQ-HDM
Number of subjects	9	9	9
Age categorical			
Units: Subjects			
Children (2-11 years)	7	8	8
Adolescents (12-17 years)	2	1	1
Age continuous			
Units: years			
arithmetic mean	7.9	8.2	8.6
standard deviation	± 2.9	± 2.2	± 2.6
Gender categorical			
Units: Subjects			
Female	4	4	2
Male	5	5	7

Reporting group values	6 SQ-HDM	9 SQ-HDM	12 SQ-HDM
Number of subjects	9	9	9
Age categorical			
Units: Subjects			
Children (2-11 years)	7	8	6
Adolescents (12-17 years)	2	1	3
Age continuous			
Units: years			
arithmetic mean	9.4	9.1	10.6
standard deviation	± 2.4	± 2	± 2.7



Gender categorical Units: Subjects			
Female	3	3	2
Male	6	6	7

<b>Reporting group values</b>	Placebo	Total	
Number of subjects	18	72	
Age categorical Units: Subjects			
Children (2-11 years)	15	59	
Adolescents (12-17 years)	3	13	
Age continuous Units: years			
arithmetic mean	9.6		
standard deviation	± 2.3	-	
Gender categorical Units: Subjects			
Female	4	22	
Male	14	50	

## End points

### End points reporting groups

Reporting group title	0.5 SQ-HDM
Reporting group description: active treatment	
Reporting group title	1 SQ-HDM
Reporting group description: active treatment	
Reporting group title	3 SQ-HDM
Reporting group description: active treatment	
Reporting group title	6 SQ-HDM
Reporting group description: active treatment	
Reporting group title	9 SQ-HDM
Reporting group description: active treatment	
Reporting group title	12 SQ-HDM
Reporting group description: active treatment	
Reporting group title	Placebo
Reporting group description: -	

### Primary: Specific IgE-blocking antibodies against D. farinae

End point title	Specific IgE-blocking antibodies against D. farinae
End point description: IgE-blocking factor: the inhibitory capacity of competing components to specific IgE-allergen binding. IgE-blocking factor is a dimensionless number which varies theoretically from 0 (no presence of IgE-blocking components) to 1 (all allergen-specific IgE antibodies are blocked from binding to allergen). The primary objective of the trial was tolerability (descriptive statistics of adverse events only). In order to comply with system requirements of a primary endpoint, this endpoint has been promoted as the primary endpoint.	
End point type	Primary
End point timeframe: change from baseline to end of trial	

End point values	0.5 SQ-HDM	1 SQ-HDM	3 SQ-HDM	6 SQ-HDM
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	9	9	8 <sup>[1]</sup>
Units: dimensionless				
arithmetic mean (standard deviation)	0.02 (± 0.08)	0.02 (± 0.08)	0.08 (± 0.1)	0.11 (± 0.1)

Notes:

[1] - 1 sample was invalid

End point values	9 SQ-HDM	12 SQ-HDM	Placebo	
------------------	----------	-----------	---------	--

Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	9	18	
Units: dimensionless				
arithmetic mean (standard deviation)	0.09 ( $\pm$ 0.14)	0.09 ( $\pm$ 0.08)	-0.01 ( $\pm$ 0.07)	

## Statistical analyses

<b>Statistical analysis title</b>	IgE-blocking factor, 12 SQ-HDM vs placebo
Statistical analysis description:	
Analysis of difference (active vs. placebo) in change from baseline in IgE-blocking factor against D. farinae	
Comparison groups	12 SQ-HDM v Placebo
Number of subjects included in analysis	27
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0048
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.035
upper limit	0.185
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	IgE-blocking factor, 9 SQ-HDM vs placebo
Statistical analysis description:	
Analysis of difference (active vs. placebo) in change from baseline in IgE-blocking factor against D. farinae	
Comparison groups	Placebo v 9 SQ-HDM
Number of subjects included in analysis	27
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0174
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.094
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.017
upper limit	0.171
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	IgE-blocking factor, 6 SQ-HDM vs placebo
Statistical analysis description:	
Analysis of difference (active vs. placebo) in change from baseline in IgE-blocking factor against D. farinae	
Comparison groups	Placebo v 6 SQ-HDM
Number of subjects included in analysis	26
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0029
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.115
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.041
upper limit	0.19
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	IgE-blocking factor, 3 SQ-HDM vs placebo
Statistical analysis description:	
Analysis of difference (active vs. placebo) in change from baseline in IgE-blocking factor against D. farinae	
Comparison groups	Placebo v 3 SQ-HDM
Number of subjects included in analysis	27
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0184
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.016
upper limit	0.164
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	IgE-blocking factor, 1 SQ-HDM vs placebo
Statistical analysis description:	
Analysis of difference (active vs. placebo) in change from baseline in IgE-blocking factor against D. farinae	
Comparison groups	Placebo v 1 SQ-HDM

Number of subjects included in analysis	27
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3453
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.036
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.039
upper limit	0.111
Variability estimate	Standard deviation

<b>Statistical analysis title</b>	IgE-blocking factor, 0.5 SQ-HDM vs placebo
Statistical analysis description:	
Analysis of difference (active vs. placebo) in change from baseline in IgE-blocking factor against D. farinae	
Comparison groups	Placebo v 0.5 SQ-HDM
Number of subjects included in analysis	27
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3861
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.034
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.043
upper limit	0.11
Variability estimate	Standard deviation

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:  
from signing informed consent to end of trial

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	11.0
--------------------	------

### Reporting groups

Reporting group title	0.5 SQ-HDM
-----------------------	------------

Reporting group description:  
active treatment

Reporting group title	1 SQ-HDM
-----------------------	----------

Reporting group description:  
active treatment

Reporting group title	3 SQ-HDM
-----------------------	----------

Reporting group description:  
active treatment

Reporting group title	6 SQ-HDM
-----------------------	----------

Reporting group description:  
active treatment

Reporting group title	9 SQ-HDM
-----------------------	----------

Reporting group description:  
active treatment

Reporting group title	12 SQ-HDM
-----------------------	-----------

Reporting group description:  
active treatment

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Serious adverse events	0.5 SQ-HDM	1 SQ-HDM	3 SQ-HDM
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Serious adverse events	6 SQ-HDM	9 SQ-HDM	12 SQ-HDM
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

<b>Serious adverse events</b>	Placebo		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 18 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	0.5 SQ-HDM	1 SQ-HDM	3 SQ-HDM
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 9 (88.89%)	9 / 9 (100.00%)	8 / 9 (88.89%)
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
chest discomfort			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
oedema mucosal			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Dysmenorrhoea			

subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 9 (11.11%)	3 / 9 (33.33%)	1 / 9 (11.11%)
occurrences (all)	1	3	1
Asthma exercise induced			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	1 / 9 (11.11%)	2 / 9 (22.22%)	4 / 9 (44.44%)
occurrences (all)	1	4	11
Dry throat			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Dyspnoea			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
hoarseness			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Nasal passage irritation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	19
Pharyngolaryngeal irritation			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Rhinitis			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	2 / 9 (22.22%)
occurrences (all)	0	1	6
Rhinitis allergic			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			



subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences (all)	0	0	2
Sneezing			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Throat irritation			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	3 / 9 (33.33%)
occurrences (all)	0	2	23
throat secretion increased			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Wheezing			
subjects affected / exposed	0 / 9 (0.00%)	2 / 9 (22.22%)	1 / 9 (11.11%)
occurrences (all)	0	2	1
Injury, poisoning and procedural complications			
Ligament sprain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
aphonia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Dizziness			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	2
Headache			
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Syncope vasovagal			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			

Ear pruritus subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 9 (11.11%) 3	1 / 9 (11.11%) 1
Eye disorders			
Conjunctival hyperaemia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1
Conjunctival irritation subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Conjunctivitis subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0
Conjunctivitis allergic subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1
Eye pruritus subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 9 (11.11%) 3
eye redness subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1
Eyelid oedema subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1
Lacrimation increased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 9 (11.11%) 6
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0
Aphthous stomatitis			

subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Diarrhoea			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Dyspepsia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	3
Glossodynia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
loose stools			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Oedema mouth			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	3 / 9 (33.33%)
occurrences (all)	0	0	8
Stomatitis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Oral pruritus			
subjects affected / exposed	3 / 9 (33.33%)	1 / 9 (11.11%)	8 / 9 (88.89%)
occurrences (all)	5	5	59
Swollen tongue			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	15
Tongue disorder			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	6
Tongue eruption			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Vomiting			

subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1
mucosal inflammation subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1
Hepatobiliary disorders Sensation of foreign body subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1
Skin and subcutaneous tissue disorders Dermatitis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1	1 / 9 (11.11%) 1
Erythema subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 36	0 / 9 (0.00%) 0	1 / 9 (11.11%) 10
Face oedema subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Pruritus subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1
Skin lesion subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Swelling face subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Urticaria subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0
Renal and urinary disorders Enuresis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1
Musculoskeletal and connective tissue disorders			

neck pain subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
<b>Infections and infestations</b>			
Bronchitis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Bronchitis viral subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	2 / 9 (22.22%) 2
Influenza subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	2 / 9 (22.22%) 7	2 / 9 (22.22%) 2
Pharyngitis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Viral infection subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
<b>Metabolism and nutrition disorders</b>			
Increased appetite subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0

<b>Non-serious adverse events</b>	6 SQ-HDM	9 SQ-HDM	12 SQ-HDM
Total subjects affected by non-serious adverse events subjects affected / exposed	9 / 9 (100.00%)	8 / 9 (88.89%)	9 / 9 (100.00%)

General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
chest discomfort			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	0	4	2
Chest pain			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	0	4	2
Malaise			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
oedema mucosal			
subjects affected / exposed	0 / 9 (0.00%)	2 / 9 (22.22%)	3 / 9 (33.33%)
occurrences (all)	0	2	4
Pyrexia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Reproductive system and breast disorders			
Dysmenorrhoea			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Asthma exercise induced			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Cough			
subjects affected / exposed	0 / 9 (0.00%)	3 / 9 (33.33%)	2 / 9 (22.22%)
occurrences (all)	0	3	2
Dry throat			

subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	5	0	0
Dyspnoea			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
hoarseness			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Nasal passage irritation			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	0	1	2
Pharyngolaryngeal irritation			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Rhinitis			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Rhinitis allergic			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Rhinorrhoea			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Sneezing			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Throat irritation			
subjects affected / exposed	7 / 9 (77.78%)	4 / 9 (44.44%)	4 / 9 (44.44%)
occurrences (all)	40	52	37
throat secretion increased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Injury, poisoning and procedural			

complications			
Ligament sprain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
aphonia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Dysgeusia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	0 / 9 (0.00%)	2 / 9 (22.22%)	1 / 9 (11.11%)
occurrences (all)	0	3	1
Syncope vasovagal			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Ear and labyrinth disorders			
Ear pruritus			
subjects affected / exposed	2 / 9 (22.22%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	5	0	26
Eye disorders			
Conjunctival hyperaemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Conjunctival irritation			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	4	0
Conjunctivitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Conjunctivitis allergic			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0



Eye pruritus			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
eye redness			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Eyelid oedema			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Lacrimation increased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	3 / 9 (33.33%)
occurrences (all)	9	1	3
Abdominal pain upper			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Aphthous stomatitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Glossodynia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
loose stools			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Oedema mouth			

subjects affected / exposed	5 / 9 (55.56%)	1 / 9 (11.11%)	6 / 9 (66.67%)
occurrences (all)	48	4	36
Stomatitis			
subjects affected / exposed	1 / 9 (11.11%)	2 / 9 (22.22%)	2 / 9 (22.22%)
occurrences (all)	6	2	3
Oral pruritus			
subjects affected / exposed	6 / 9 (66.67%)	6 / 9 (66.67%)	6 / 9 (66.67%)
occurrences (all)	75	51	69
Swollen tongue			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tongue disorder			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tongue eruption			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Toothache			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
mucosal inflammation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Sensation of foreign body			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Erythema			

subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences (all)	0	0	3
Face oedema			
subjects affected / exposed	3 / 9 (33.33%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	3	2	1
Pruritus			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	0	3	1
Skin lesion			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Swelling face			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	0	5	1
Urticaria			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Renal and urinary disorders			
Enuresis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
neck pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Bronchitis viral			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Nasopharyngitis			

subjects affected / exposed	2 / 9 (22.22%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Pharyngitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Viral infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Increased appetite			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Placebo		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	17 / 18 (94.44%)		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Chest discomfort			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Chest pain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Malaise			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
oedema mucosal			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Pyrexia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Reproductive system and breast disorders			
Dysmenorrhoea			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	6 / 18 (33.33%)		
occurrences (all)	6		
Asthma exercise induced			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Cough			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	7		
Dry throat			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dyspnoea			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
hoarseness			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Nasal passage irritation			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Pharyngolaryngeal irritation			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Rhinitis			

subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Rhinitis allergic			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Rhinorrhoea			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Sneezing			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Throat irritation			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
throat secretion increased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Wheezing			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Injury, poisoning and procedural complications			
Ligament sprain			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Nervous system disorders			
aphonia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dizziness			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dysgeusia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	2		
Headache			

subjects affected / exposed	5 / 18 (27.78%)		
occurrences (all)	11		
Syncope vasovagal			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Ear and labyrinth disorders			
Ear pruritus			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Eye disorders			
Conjunctival hyperaemia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Conjunctival irritation			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Conjunctivitis			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	3		
Conjunctivitis allergic			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Eye pruritus			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	4		
eye redness			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Eyelid oedema			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Lacrimation increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			

Abdominal pain			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	17		
Abdominal pain upper			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Aphthous stomatitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Diarrhoea			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Dyspepsia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Glossodynia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
loose stools			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Oedema mouth			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Stomatitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Oral pruritus			
subjects affected / exposed	4 / 18 (22.22%)		
occurrences (all)	6		
Swollen tongue			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Tongue disorder			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		



Tongue eruption subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Toothache subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 2		
Vomiting subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
mucosal inflammation subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Hepatobiliary disorders Sensation of foreign body subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Skin and subcutaneous tissue disorders Dermatitis subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Erythema subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Face oedema subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Pruritus subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Skin lesion subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Swelling face subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Urticaria			

subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Renal and urinary disorders Enuresis subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Musculoskeletal and connective tissue disorders neck pain subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Infections and infestations Bronchitis subjects affected / exposed occurrences (all)  Bronchitis viral subjects affected / exposed occurrences (all)  Influenza subjects affected / exposed occurrences (all)  Nasopharyngitis subjects affected / exposed occurrences (all)  Pharyngitis subjects affected / exposed occurrences (all)  Upper respiratory tract infection subjects affected / exposed occurrences (all)  Viral infection subjects affected / exposed occurrences (all)  Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	2 / 18 (11.11%) 2  0 / 18 (0.00%) 0  0 / 18 (0.00%) 0  0 / 18 (0.00%) 0  0 / 18 (0.00%) 0  1 / 18 (5.56%) 1  0 / 18 (0.00%) 0  0 / 18 (0.00%) 0		
Metabolism and nutrition disorders			

Increased appetite subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
--	---------------------	--	--

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
23 October 2007	The amendment was proposed after the evaluation of subjects included in the 2nd cohort (dose group 1 SQ-HDM).Inclusion of two additional dose groups: 9 SQ-HDM and 12 SQ-HDM. Both doses were below the maximum tolerable dose found in adults in the MT-01 trial

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Not applicable
----------------

Notes: